Based on the earnings call transcript, I anticipate a slightly positive short-term impact on J&J's stock price. Key positives include strong pharmaceutical segment growth (10.9% operational growth), successful new product launches like XARELTO and ZYTIGA, improved gross margins, and maintained full-year guidance. However, this is somewhat tempered by challenges in the MD&D segment (flat growth), slower growth in BRIC markets, and pricing pressures in orthopedics. The management team demonstrated confidence and provided clear strategies for growth while acknowledging and addressing challenges.

[1]